Latvian cancer treatment drug receives EC grant for distribution in the EU

Rigvir Holding company Latima has been provided with a grant of the European Commission’s Horizon 2020 programme for the purpose of commercialization of Rigvir cancer treatment drug on the European market.

Karlis Urbans, financial director for Rigvir, notes: «Rigvir is a safe and effective cancer treatment drug, which is desperately needed to help cancer patients in Europe and elsewhere. This unique drug is currently registered in three countries of the world. This means it is available to patients in other countries only through medical tourism. We hope this grant will allow is to make Rigvir more accessible for people suffering from cancer across all of Europe».

Horizon 2020 is the most massive programme organized by the European Commission for research and innovations. The programme’s budget is EUR 80 billion for seven years. Latima has received funding as part of the sub-programme ‘Support of bio-technologies to assist with the creation of turnover of new products on the European market’. This programme is administered by the European Committee in Brussels. It is open to all participants across the entire European Union.

Rigvir Holding unites companies working in research and development of a unique Latvian-produced cancer treatment drug Rigvir and its commercialization on foreign markets. Rigvir is one of the most significant accomplishments of Latvia’s science in oncology. This drug is registered for treatment of melanomas. In practice, however, it is also used to treat multiple other kinds of malignant tumours. Since 2011, Rigvir is 100% compensated to Latvian patients diagnosed with malignant skin melanoma. In 2015, Rigvir was added to clinical guidelines approved by the National Health Service. Rigvir has since been registered in Georgia and Armenia.

BNN 

Comment